![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Despite significant advances in the systemic treatment of metastatic renal cell carcinoma, long-term survival remains low. A potential way to improve outcomes in selected cases is the use of metastasectomy, which is part of the multimodal treatment of this disease. Although the evidence supporting this approach is limited, we believe it is a reasonable option for certain patients. This review summarizes the evidence supporting this approach.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Key issues
• Despite significant advances in the systemic treatment of metastatic renal cell carcinoma (RCC), long-term survival remains low.
• Metastasectomy forms part of the multimodal treatment of metastatic RCC and appears to improve long-term survival in highly selected patients.
• The evidence supporting metastasectomy in RCC is limited with the majority of studies being retrospective and subject to inherent selection bias.
• The role of metastasecomy in RCC in the era of targeted therapy remains unclear with more research needed to assess its efficacy and safety.
• Currently, the decision of whether a patient should proceed with metastasectomy needs to be assessed on a case-by-case basis by the multidisciplinary team after consideration of the advantages and disadvantages of this approach.